Skip to content

the Clinical Effect of TCM Sniffing Therapy Combined With Electroacupuncture in PSCI

the Clinical Effect of TCM Sniffing Therapy Combined With Electroacupuncture in the Treatment of Cognitive Impairment After Stroke

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06313866
Enrollment
220
Registered
2024-03-15
Start date
2024-04-01
Completion date
2025-06-01
Last updated
2025-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

The patients with cognitive impairment after stroke were divided into control group, electroacupuncture group, olfactory therapy group, electroacupuncture combined with olfactory therapy group, and sham group with 35 people in each group. After the end of the treatment, the clinical efficacy was evaluated.

Detailed description

The patients with cognitive impairment after stroke were divided into control group, electroacupuncture group, olfactory therapy group, and electroacupuncture combined with olfactory therapy group, and sham group with 35 people in each group. All patients were treated with conventional drugs and general supportive treatment, and on the basis of this, the electroacupuncture group was given electroacupuncture treatment at bilateral Fengchi and Gongxue, the smell suction therapy group was given the intervention of volatile oil nasal suction of Acorus calamus, and the electroacupuncture group combined with smell and suction therapy group was given electroacupuncture treatment at the same time as the electroacupuncture treatment of bilateral Fengchi and Gongxue. In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture. After the 1 month innervation,the main efficacy indicators: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Barthel Index (MBI) score, and the secondary efficacy indicators: Transcranial Doppler (TCD), near-infrared functional brain imaging , magnetic resonance examination, the heart rate,blood pressure and the State Trait Anxiety Inventory (STAI)are collected.

Interventions

DIETARY_SUPPLEMENTcontrol

Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.

OTHERElectronuchal acupuncture group treatment

Electronuchal acupuncture

OTHERSmell therapy group treatment

nasal suction intervention with volatile oil of Acorus calamus

OTHERElectronuchal acupuncture combined with smell and inhalation therapy group treatment

On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.

OTHERSham stimulation

In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.

Sponsors

Hangzhou Medical College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No

Inclusion criteria

* (1) Stroke as per the TCM definition, presenting symptoms include unilateral paresis or paralysis, sensory deficits, speech impairment, and hemianopsia. PSCI diagnosis involves clinically significant deficits in at least one cognitive domain and severe disruption of instrumental ADLs/ADLs.; (2) The scores on the MMSE scale must adhere to the following criteria: Less than 17 points for individuals with illiteracy, less than 20 points for those with primary school education, and less than 24 points for individuals with a middle school education or higher.; (3) Aged under 70 years; (4) No history of mental illness, clear consciousness, stable vital signs, and able to complete the scale assessment; (5) Within 6 months post-stroke, diagnosed as a patient in the recovery period of cerebral infarction (or cerebral hemorrhage) at admission; (6) Signed informed consent by the patient or their family.

Exclusion criteria

* (1) Transient ischemic attack; (2) Subarachnoid hemorrhage; (3) History of severe liver or kidney diseases, mental illness, epilepsy, asthma, or obstructive pulmonary diseases; (4) Occurrence of cognitive impairment prior to stroke; (5) Severe communication barriers; (6) Substance abuse or heavy alcohol consumption; (7) Implanted cardiac pacemakers or other electronic devices.

Design outcomes

Primary

MeasureTime frameDescription
MoCA0,4 weeks after the intervention, 8 weeks after the interventionMontreal Cognitive Assessment Scale

Secondary

MeasureTime frameDescription
MBI0,4 weeks after the intervention,8 weeks after the interventionBarthel index score
TCD0,4 weeks after the interventionTranscranial Doppler examination
MMSE0,4 weeks after the intervention,8 weeks after the interventionMini-Mental State Examination
Magnetic resonance scanning0,4 weeks after the interventionMagnetic resonance scanning
the State Trait Anxiety Inventory (STAI)0,4 weeks after the interventionthe State Trait Anxiety Inventory (STAI)
Near-infrared functional imaging of the brain0,4 weeks after the interventionNear-infrared functional imaging of the brain

Countries

China

Contacts

Primary ContactXinyun Dr LI, Doctor
lxyjasmine2010@163.com8618069783240

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026